Research and development (R&D) activities are anticipated to drive growth in the adenosine antagonists market by identifying novel therapeutic applications, such as in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems are expected to enhance efficacy and safety profiles, thereby increasing adoption. Furthermore, advancements through clinical trials and regulatory approvals will bolster market credibility and expand demand.
New York, USA, Dec. 09, 2024 (GLOBE NEWSWIRE) — Adenosine Antagonists Clinical Trial Pipeline Analysis: 10+ Key Companies Shaping the Future of Adenosine Antagonists Therapeutics | DelveInsight
Research and development (R&D) activities are anticipated to drive growth in the adenosine antagonists market by identifying novel therapeutic applications, such as in neurodegenerative diseases, oncology, and cardiovascular disorders. Innovations in formulation and delivery systems are expected to enhance efficacy and safety profiles, thereby increasing adoption. Furthermore, advancements through clinical trials and regulatory approvals will bolster market credibility and expand demand.
DelveInsight’s ‘
A snapshot of the Pipeline Adenosine Antagonist Drugs mentioned in the report:
| Drugs | Company | Phase | Indication | RoA |
| Etrumadenant | Arcus Biosciences | II | Colorectal cancer; Non-small cell lung cancer; Pancreatic cancer; Rectal cancer | Oral |
| Ciforadenant | Corvus Pharmaceuticals | II | Renal cell carcinoma | Oral |
| Inupadenant | iTeos Therapeutics | II | Non-small cell lung cancer | Oral |
| PORT-6 | Portage Biotech | I/II | Non-small cell lung cancer; Prostate cancer; Renal cell carcinoma | Oral |
Learn more about the emerging adenosine antagonists @ Adenosine Antagonists Clinical Trials
Adenosine Antagonists Therapeutics Assessment
The adenosine antagonists pipeline report proffers an integral view of the emerging adenosine antagonists segmented by stage, product type, molecule type, and route of administration.
Scope of the Adenosine Antagonists Pipeline Report
- Coverage: Global
- Therapeutic Assessment By Product Type: Mono, Combination, Mono/Combination
- Therapeutic Assessment By Clinical Stages: Discovery, Pre-clinical, Phase I, Phase II, Phase III
- Therapeutics Assessment By Route of Administration: Oral, Parenteral, Intravenous, Subcutaneous, Topical
- Therapeutics Assessment By Molecule Type: Monoclonal antibody, Peptides, Polymer, Small molecule, Gene therapy
- Key Adenosine Antagonists Companies: Arcus Biosciences, Corvus Pharmaceuticals, Portage Biotech, Palobiofarm, iTeos Therapeutics, and others
- Key Adenosine Antagonists Pipeline Therapies: Etrumadenant, Ciforadenant, PORT-6, PORT 7, PBF-680, Inupadenant, and others
Dive deep into rich insights for new adenosine antagonists, visit @ Adenosine Antagonists Drugs
Table of Contents
| 1. | Adenosine Antagonists Pipeline Report Introduction |
| 2. | Adenosine Antagonists Pipeline Report Executive Summary |
| 3. | Adenosine Antagonists Pipeline: Overview |
| 4. | Analytical Perspective In-depth Commercial Assessment |
| 5. | Adenosine Antagonists Clinical Trial Therapeutics |
| 6. | Adenosine Antagonists Pipeline: Late-Stage Products (Pre-registration) |
| 7. | Adenosine Antagonists Pipeline: Late-Stage Products (Phase III) |
| 8. | Adenosine Antagonists Pipeline: Mid-Stage Products (Phase II) |
| 9. | Adenosine Antagonists Pipeline: Early-Stage Products (Phase I) |
| 10. | Adenosine Antagonists Pipeline Therapeutics Assessment |
| 11. | Inactive Products in the Adenosine Antagonists Pipeline |
| 12. | Company-University Collaborations (Licensing/Partnering) Analysis |
| 13. | Key Companies |
| 14. | Key Products in the Adenosine Antagonists Pipeline |
| 15. | Unmet Needs |
| 16. | Market Drivers and Barriers |
| 17. | Future Perspectives and Conclusion |
| 18. | Analyst Views |
| 19. | Appendix |
For further information on the adenosine antagonists pipeline therapeutics, reach out @ Adenosine Antagonists Therapeutics
Related Reports
Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Metastatic Castration-Resistant Prostate Cancer Market
Metastatic Castration-Resistant Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCRPC companies including AstraZeneca, Merck Sharp & Dohme, Hinova Pharmaceuticals, Pfizer, Astellas Pharma, Modra Pharmaceuticals, AB Science, Eli Lilly and Company, Zr Pharma & GmbH, Bristol-Myers Squibb, Ipsen, Exelixis, Takeda, Janssen Research & Development, Tesaro, Lantheus Holdings, Kintor Pharmaceutical, MacroGenics, Daiichi Sankyo, Madison Vaccines, Novartis, Point Biopharma, Xencor, Essa Pharma, Telix International, Bayer, Arvinas, among others.
Metastatic Prostate Cancer Market
Metastatic Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report deliver an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key metastatic prostate cancer companies including AstraZeneca, Arvinas, Madison Vaccines, Phosplatin Therapeutics, Hinova Pharmaceuticals, Bristol Myers Squibb, Merck, MacroGenics, Daiichi Sankyo, Seagen, Taiho Pharmaceutical, Modra Pharmaceuticals, Xencor, Point Biopharma, Lantheus Holdings, Zenith Epigenetics, Essa Pharma, Telix Pharmaceuticals, Kintor Pharmaceutical, AB Science, Eli Lilly and Company, Exelixis among others.
Metastatic Castration-Sensitive Prostate Cancer Market
Metastatic Castration-Sensitive Prostate Cancer Market Insights, Epidemiology, and Market Forecast – 2034 report delivers an in-depth understanding of the disease, historical and forecasted epidemiology, market share of the individual therapies, and key mCSPC companies including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others.
Metastatic Castration-Sensitive Prostate Cancer Pipeline
Metastatic Castration-Sensitive Prostate Cancer Pipeline Insight – 2024 report provides comprehensive insights about the pipeline landscape, including clinical and non-clinical stage products, and the key mCSPC companies, including Myovant Sciences, Pfizer, Bayer, Orion, Novartis, AstraZeneca, Pfizer, Janssen, Merck, Eli Lilly, among others.
Oncology Conference Coverage Services
DelveInsight’s Oncology Conference Coverage Services offer a thorough analysis of outcomes from major events like ASCO, ESMO, ASH, AACR, ASTRO, SOHO, SITC, the European CAR T-cell Meeting, and IASLC. This detailed examination provides businesses with essential insights for competitive intelligence and market trend forecasting, supporting the formulation of future strategies.
Other Business Consulting Services
Healthcare Competitive Intelligence
Healthcare Portfolio Management
Case Study
Learn how the engagement with respected KOLs bolstered the client’s reputation as a leader in the pharma industry at KOL Profiling
About DelveInsight
DelveInsight is a leading Business Consultant, and Market Research firm focused exclusively on life sciences. It supports pharma companies by providing comprehensive end-to-end solutions to improve their performance.
CONTACT: Contact Us Shruti Thakur info@delveinsight.com +14699457679 www.delveinsight.com
